

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction

Rebecca J. Woolley¹, Daan Ceelen¹, Wouter Ouwkerk^{2,3}, Jasper Tromp^{1,2,4}, Sylwia M. Figarska¹, Stefan D. Anker^{5,6}, Kenneth Dickstein^{7,8}, Gerasimos Filippatos^{9,10}, Faiez Zannad¹¹, Marco Metra¹², Leong Ng¹³, Nilesh Samani¹³, Dirk J van Veldhuisen¹, Chim Lang¹⁴, Carolyn S. Lam^{1,2,4}, and Adriaan A. Voors^{1*}

¹Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ²National Heart Centre Singapore, Singapore; ³Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam, University Medical Centers, University of Amsterdam, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam, The Netherlands; ⁴Duke-NUS Medical School, Singapore; ⁵Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany; ⁶German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; ⁷University of Bergen, Bergen, Norway; ⁸Stavanger University Hospital, Stavanger, Norway; ⁹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; ¹⁰University of Cyprus, School of Medicine, Nicosia, Cyprus; ¹¹Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and F-CRIN INI CRCT, Nancy, France; ¹²Institute of Cardiology, ASST Spedali Civili di Brescia, and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; ¹³Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, and NIHR Leicester Biomedical Research Centre, Leicester, UK; and ¹⁴School of Medicine Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK

Received 22 October 2020; revised 2 November 2021; accepted 26 February 2021; online publish-ahead-of-print 17 March 2021

Aims

The lack of effective therapies for patients with heart failure with preserved ejection fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to identify distinct pathophysiologic clusters of HFpEF based on circulating biomarkers.

Methods and results

We performed an unsupervised cluster analysis using 363 biomarkers from 429 patients with HFpEF. Relative differences in expression profiles of the biomarkers between clusters were assessed and used for pathway over-representation analyses. We identified four distinct patient subgroups based on their biomarker profiles: cluster 1 with the highest prevalence of diabetes mellitus and renal disease; cluster 2 with oldest age and frequent age-related comorbidities; cluster 3 with youngest age, largest body size, least symptoms and lowest N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels; and cluster 4 with highest prevalence of ischaemic aetiology, smoking and chronic lung disease, most symptoms, as well as highest NT-proBNP and troponin levels. Over a median follow-up of 21 months, the occurrence of death or heart failure hospitalization was highest in clusters 1 and 4 (62.1% and 62.8%, respectively) and lowest in cluster 3 (25.6%). Pathway over-representation analyses revealed that the biomarker profile of patients in cluster 1 was associated with activation of inflammatory pathways while the biomarker profile of patients in cluster 4 was specifically associated with pathways implicated in cell proliferation regulation and cell survival.


Conclusion

Unsupervised cluster analysis based on biomarker profiles identified mutually exclusive subgroups of patients with HFpEF with distinct biomarker profiles, clinical characteristics and outcomes, suggesting different underlying pathophysiological pathways.

*Corresponding author. Department of Cardiology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. Tel: +31 50 3616161, Email: a.a.voors@umcg.nl

[Correction added on 08 September 2021 after first online publication: The first and last name of the 10th author, Marco Metra, was originally published in the wrong order and has now been corrected in this version.]

Graphical Abstract



In patients with heart failure with preserved ejection fraction (HFpEF), machine learning techniques were able to identify four subgroups of HFpEF patients based on their protein biomarkers. These subgroups differed in comorbidity patterns and outcome, with 'renal disease/diabetes' and chronic obstructive pulmonary disease (COPD) subgroups at highest risk of adverse outcomes, while 'elderly' and 'young/obese' subgroups were at lower risk. These HFpEF subgroups also had remarkably differing protein biomarker profiles, suggesting differing underlying mechanisms. Even though these findings do not have direct clinical implications, the identification of HFpEF subgroups, with differing underlying pathological mechanisms could aid in the identification of novel treatment targets in the future.

Keywords

Heart failure • Machine learning • Heart failure with preserved ejection fraction • Cluster analysis

Introduction

Heart failure (HF) with preserved ejection fraction (HFpEF) is labelled as the 'single largest unmet need in cardiovascular medicine'.¹ Despite accounting for approximately half of HF cases, an effective therapy for HFpEF is yet to be found. Several pathological mechanisms have been proposed as underlying mechanisms in HFpEF including systemic microvascular inflammation, cardio-metabolic abnormalities and cellular and extracellular structural changes. However, studies targeting these mechanisms have yielded mixed results and have yet to show improved prognosis in these patients.²

The 'heterogeneity' of HFpEF has been cited as a reason for clinical trials not being effective in HFpEF patients, suggesting that a 'one size fits all' approach may not work in HFpEF.^{1,3} The pathophysiology of HFpEF is highly complex.⁴ The identification of mutually exclusive subgroups of patients with HFpEF based on their underlying pathophysiology may allow for the development of targeted treatment options. Several studies have sought to identify subgroups of patients with HFpEF using machine learning techniques, classifying these patients into clinical phenotypes and advocated phenotype specific treatment of these subgroups.⁵⁻⁹ Such techniques have managed to identify subgroups of patients with similar phenotypic characteristics with differences in outcome. However, subgroups based on clinical characteristics do

not necessarily represent differences in pathological mechanisms. Similar to HFpEF, HF with reduced ejection fraction represents a heterogeneous group comprising patients with a multitude of HF aetiologies, yet a common pathway of systemic neuroendocrine activation.² Therefore, there are limitations in using this approach.

We hypothesised that unsupervised machine learning techniques applied to protein biomarkers in HFpEF patients would allow the identification of biological HFpEF subgroups, representing different pathological mechanisms in HFpEF.

Methods

Patient population

This study utilized patients from the Scottish cohort of BIostat-CHF, which is described elsewhere.¹⁰ In brief, the Scottish cohort of BIostat-CHF includes 1738 patients from six centres in Scotland, United Kingdom. Patients were required to be ≥ 18 years of age, diagnosed with HF and previously admitted with HF requiring diuretic treatment. Patients were also sub-optimally treated with angiotensin-converting enzyme inhibitors and beta-blockers with an anticipated up-titration over the following 3 months.

Of the 1738 patients included, only patients with a left ventricular ejection fraction of $\geq 50\%$ were included. Of the remaining 441

patients, there were 12 patients with missing biomarker values. Subsequent analyses were done with the remaining 429 patients.

Clinical and biomarker measurements

Medical history, physical examinations, echocardiography and laboratory tests were recorded at baseline as previously described.¹⁰

An overview of biomarkers and their pathophysiological functions are presented in the online supplementary *Figures S1* and *S2*. Four biomarker panels comprising each of 92 protein biomarkers provided by the Olink Bioscience analysis service (Uppsala, Sweden) were measured. These respective panels were Cardiovascular II, Cardiovascular III, Immune response and Oncology II panels. The proteins were profiled using Olink Proseek® Multiplex Inflammatory^{96x96} platform. The Proseek® kit uses proximity extension assay technology, whereby oligonucleotide-labelled antibody probe pairs bind to their respective targets. Quantification was achieved using a Fluidigm BioMark™ real-time polymerase chain reaction platform. The platform provides normalized protein expression (log₂-normalized), rather than an absolute quantification.

Across the panels there were several duplicates, therefore the mean of normalized protein expression duplicates was used (online supplementary material). Further analyses were completed using the set of 363 non-redundant protein biomarkers.

Statistical analysis

A more comprehensive description of statistical methods used is provided in online supplementary material. In short, the primary aim of this study was to identify mutually exclusive subgroups of patients based on their biomarker profile using 363 biomarkers, which are referred to as clusters. Principle component analysis was performed in order to reduce biomarker dimensions and collinearity. Clustering was performed on principle components with an eigenvalue of one or above using a hierarchical clustering algorithm. The NbClust package in R, which utilises an array of different indexes, was used in order to

determine the optimal number of clusters. The number most often selected by these indexes is then selected as the optimal number of clusters.^{11,12}

Differences between clinical characteristics of the clusters were compared using one-way analysis of variance (ANOVA), the Kruskal–Wallis test or chi-squared test where appropriate. Differences between clusters biomarker means were plotted using a heatmap after z-standardization.

The association of cluster membership with all-cause mortality and HF hospitalization was investigated using Kaplan–Meier curves and the log-rank test. For multivariable analyses, Cox-regression models were performed, correcting for age, sex and previous HF hospitalization and New York Heart Association (NYHA) class.

Relative differences in protein biomarker levels between clusters were assessed using the *Limma* package in R.¹³ Proteins were considered differentially expressed at a log₂ fold-change cut-off of 0.8 and false discovery rate corrected *P*-value of <0.05. Protein biomarkers identified to be differentially expressed were further investigated for pathway over-representation.

Over-representation was assessed using ClueGo (in Gene Ontology in biological processes, KEGG and Reactome pathways).¹⁴ This was performed using the hypergeometric test and the default Bonferroni step down method for multiple testing corrections. The whole annotation option was used as a reference set and only biological processes with a corrected *P*-value ≤0.05 were considered significant.

Results

Clustering outcomes

The optimal number of clusters was six (online supplementary *Figure S3*, *S4* and *S5*). Due to the small size, clusters 5 and 6 ($n = 3$ and $n = 2$, respectively, online supplementary *Table S1*) were excluded from the downstream analyses which focused on the remaining four patient clusters. Expression patterns of biomarkers across the four clusters are depicted in the heatmap in *Figure 1*. Lower levels of biomarker means are depicted in lighter colours, while darker colours represent higher biomarker levels. Cluster 1 biomarkers are markedly higher compared to other clusters, while cluster 3 shows low levels of almost all biomarkers.

Clinical characteristics

Baseline characteristics of the four clusters are presented in *Table 1*. Patients in cluster 1 had the highest prevalence of chronic kidney disease (CKD, 73.7%) and diabetes mellitus (53.4%), and had the highest plasma concentrations of creatinine, glucose, gamma-glutamyl transferase and growth differentiation factor-15. Patients in cluster 2 were the eldest (mean age 80 years), with a high frequency of age-related comorbidities such as atrial fibrillation (46.5%) and hypertension (72.3%), however these did not reach significance. Patients in cluster 3 were youngest (mean age 74 years), had the lowest prevalence of most comorbidities, except obesity (mean body mass index 30.4 kg/m², mean body surface area 2.02 m²), were the least symptomatic and had the lowest plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations (median 591 pg/L). Patients in cluster 4 had the highest prevalence of chronic obstructive pulmonary disease (COPD)




Table 1 Baseline characteristics stratified by heart failure with preserved ejection fraction cluster

	Cluster 1	Cluster 2	Cluster 3	Cluster 4	P-value
<i>n</i>	58	159	164	43	
Demographics					
Age (years)	79.0 [73.0–82.0]	80.0 [72.5–86.5]	74.0 [66.8–81.0]	79.0 [71.5–83.0]	<0.001
Male sex	35 (60.3%)	84 (52.8%)	93 (56.7%)	26 (60.5%)	0.689
BMI (kg/m ²)	29.1 [24.8–33.2]	28.4 [24.2–34.2]	30.4 [25.4–34.7]	29.4 [25.4–33.4]	0.408
BSA (m ²)	1.97 [1.80–2.11]	1.85 [1.68–2.01]	2.02 [1.79–2.21]	2.01 [1.79–2.13]	0.032
Ischaemic aetiology	31 (54.4%)	99 (65.1%)	101 (66.4%)	31 (72.1%)	0.272
Cardiomyopathy	4 (7.02%)	4 (2.63%)	3 (1.97%)	1 (2.33%)	0.293
NYHA class					<0.001
I	0 (0.0%)	0 (0.0%)	4 (2.44%)	0 (0.0%)	
II	15 (25.9%)	37 (23.3%)	72 (43.9%)	8 (18.6%)	
III	32 (55.2%)	83 (52.2%)	65 (39.6%)	24 (55.8%)	
IV	11 (19.0%)	39 (24.5%)	23 (14.0%)	11 (25.6%)	
Medical history					
Anaemia	27 (46.6%)	72 (45.9%)	50 (30.9%)	22 (51.2%)	0.012
Atrial fibrillation	31 (54.4%)	74 (46.5%)	67 (41.1%)	24 (55.8%)	0.185
Diabetes	31 (53.4%)	53 (33.3%)	57 (35.2%)	15 (35.7%)	0.048
COPD	11 (19.0%)	44 (27.7%)	36 (22.1%)	18 (41.9%)	0.034
CKD	42 (73.7%)	107 (67.7%)	34 (21.5%)	23 (53.5%)	<0.001
Hypertension	42 (72.4%)	115 (72.3%)	102 (62.2%)	31 (72.1%)	0.190
Malignancy	6 (10.5%)	5 (3.14%)	6 (3.66%)	2 (4.65%)	0.141
Obesity	25 (43.9%)	69 (43.7%)	86 (53.8%)	19 (44.2%)	0.270
Stroke	13 (22.4%)	31 (19.5%)	30 (18.4%)	9 (21.4%)	0.913
Past/current smokers	25 (43.9%)	72 (45.9%)	69 (42.3%)	28 (65.1%)	0.063
Signs and symptoms					
Extent of peripheral oedema					0.121
Not present	7 (13.0%)	46 (31.7%)	54 (37.0%)	9 (22.5%)	
Ankle	22 (40.7%)	52 (35.9%)	42 (28.8%)	15 (37.5%)	
Below knee	18 (33.3%)	34 (23.4%)	40 (27.4%)	12 (30.0%)	
Above knee	7 (13.0%)	13 (8.97%)	10 (6.85%)	4 (10.0%)	
JVP elevated (%)	24 (49.0%)	41 (29.1%)	45 (34.1%)	9 (25.7%)	0.035
Pulmonary congestion with rales	36 (64.3%)	75 (48.4%)	70 (45.2%)	32 (74.4%)	0.001
Laboratory					
Haemoglobin (g/dL)	12.2 [11.2–13.5]	12.5 [10.9–13.5]	13.3 [12.3–14.4]	12.5 [10.8–13.8]	<0.001
Leucocytes (10 ⁹ /L)	7.45 [5.55–10.0]	7.55 [5.93–9.00]	7.25 [5.90–8.80]	9.90 [7.50–12.8]	<0.001
Creatinine (μmol/L)	126 [96.0–148]	112 [88.0–142]	81.5 [66.8–94.2]	96.0 [79.0–121]	<0.001
Urea (mmol/L)	11.1 [7.90–15.3]	9.80 [7.93–13.5]	6.60 [5.47–8.43]	10.2 [7.90–13.9]	<0.001
eGFR (mL/min/1.73 m ²)	46.0 [36.0–59.5]	51.0 [38.0–60.0]	60.0 [60.0–60.0]	58.0 [48.0–60.0]	<0.001
Gamma-GT (U/L)	61.0 [39.5–138]	44.0 [27.0–80.0]	35.0 [25.0–62.0]	47.0 [32.0–94.8]	0.001
Glucose (mmol/L)	7.90 [5.60–10.6]	6.60 [5.60–9.10]	6.05 [5.10–8.40]	7.80 [6.00–10.2]	0.002
Iron (μmol/L)	8.00 [6.00–12.0]	9.00 [6.00–13.0]	13.0 [8.00–16.0]	8.00 [4.25–11.8]	<0.001
Ferritin (ng/mL)	154 [58.0–270]	93.0 [43.0–209]	94.5 [35.5–202]	98.0 [52.0–262]	0.162
NT-proBNP (pg/L)	1720 [544–4831]	1304 [526–2938]	591 [234–1621]	2175 [898–4542]	<0.001
GDF-15 (pg/mL)	5877 [3412–8555]	3510 [2507–5228]	2174 [1532–2982]	3777 [2815–5970]	<0.001
Troponin T (ng/L)	45.0 [26.9–79.6]	32.6 [18.9–63.1]	19.0 [12.4–31.3]	46.2 [30.4–271]	<0.001

BMI, body mass index; BSA, boy surface area; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; GT, glutamyl transferase; JVP, jugular venous pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.

(41.9%), smoking (65.1%) and ischaemic aetiology (72.1%); were the most symptomatic and had the highest levels of NT-proBNP (median 2175 pg/L) and troponin (median 46.2 ng/L). Table 2 shows the echocardiographic characteristics of the four clusters. In terms of cardiac structure and function, clusters were remarkably similar, except for a lower estimated right ventricular systolic pressure and tricuspid regurgitation velocity in patients from cluster 3.

Differential expression analysis and pathway over-representation analysis

In cluster 1, there were 29 proteins that were significantly up-regulated compared to the rest of the clusters (Figure 2a online supplementary Table S2). At the fold-change cut-off, no proteins were found to be significantly up- or down-regulated in cluster 2

Table 2 Echocardiography stratified by cluster

	Cluster 1	Cluster 2	Cluster 3	Cluster 4	P-value
n	58	159	164	43	
LVEF (%)	54.0 [50.0–60.0]	55.0 [50.0–60.0]	54.5 [50.0–60.0]	55.0 [50.0–60.0]	0.953
LVEDD (mm)	46.2 (6.52)	47.9 (6.96)	48.6 (7.71)	48.5 (7.25)	0.359
LVESD (mm)	30.0 [26.0–33.5]	31.0 [24.0–37.0]	33.0 [26.0–37.5]	30.0 [24.5–38.5]	0.844
IVSd (mm)	13.0 [12.0–15.0]	13.0 [11.8–15.0]	13.0 [10.0–15.0]	13.0 [12.8–15.0]	0.502
PWd (mm)	12.0 [11.0–13.0]	11.0 [9.00–14.0]	10.0 [9.00–13.0]	12.0 [10.0–13.0]	0.477
Left atrial diameter (mm)	43.9 (6.30)	45.0 (7.15)	43.2 (7.27)	44.6 (6.87)	0.318
E/A ratio	0.80 [0.70–1.10]	1.00 [0.70–1.40]	0.90 [0.70–1.20]	0.90 [0.80–1.10]	0.671
IVC dilated	10 (17.2%)	26 (16.4%)	26 (15.9%)	5 (11.6%)	0.876
Right atrial pressure (mmHg)	10.0 [7.25–17.2]	10.0 [7.00–13.0]	9.00 [7.00–10.0]	9.00 [8.00–10.0]	0.440
RVSP (mmHg)	49.0 [39.0–63.5]	43.0 [35.0–55.0]	37.0 [30.0–49.0]	47.0 [37.0–52.0]	0.004
Right ventricular diameter ≥44 mm	11 (21.6%)	26 (20.5%)	27 (19.4%)	8 (22.2%)	0.978
Tricuspid regurgitation gradient	36.0 [28.0–50.0]	34.0 [27.0–42.5]	29.0 [24.0–38.0]	40.0 [32.0–45.5]	0.004

IVC, inferior vena cava; IVSd, interventricular septum thickness; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PWd, posterior wall thickness; RVSP, right ventricular systolic pressure.




Figure 2 Differentially expressed proteins relative to other heart failure with preserved ejection fraction clusters. (A) Cluster 1 vs. clusters 2–4; (B) cluster 2 vs. clusters 1, 3 and 4; (C) cluster 3 vs. clusters 1, 2 and 4; and (D) cluster 4 vs. clusters 1–3. FC, fold change; FDR, false discovery rate.

compared to the other clusters (Figure 2b). A total of 26 proteins were discovered to be significantly down-regulated in cluster 3 (Figure 2c, online supplementary Table S3). In cluster 4, one protein was significantly down-regulated, while 34 proteins were found to be significantly up-regulated (Figure 2d, online supplementary Table S4).

Pathway over-representation analysis of the differentially expressed proteins per cluster yielded several significant pathways.

The 29 differentially expressed proteins in cluster 1 yielded four significant biological processes ($P < 0.001$): ‘tumour necrosis factor-activated receptor activity’; ‘TNFs bind to their physiological receptors’; ‘regulation of natural killer cell mediated immunity’ and ‘regulation of regulatory T cell differentiation’. The 26 down-regulated proteins in cluster 3 were significantly associated with the following biological processes ($P < 0.001$): ‘tumour necrosis factor-activated receptor activity’, ‘viral protein

interaction with cytokine and cytokine receptor' and 'regulation of cardiac muscle hypertrophy'. The 34 up-regulated proteins in cluster 4 were significantly associated with six biological processes ($P < 0.001$): 'protein serine/threonine kinase inhibitor activity'; 'regulation of receptor internalisation'; 'viral myocarditis'; 'Kaposi sarcoma-associated herpes virus infection'; 'PI3K/AKT signalling in cancer' and 'positive regulation of phosphatidylinositol 3-kinase activity'.

Clinical outcome

After a median follow-up of 21 months, approximately 44% of patients either had been hospitalized for HF or died. The occurrence of death or HF hospitalization was highest in clusters 1 and 4 (62.1% and 62.8%, respectively) and lowest in cluster 3 (25.6%). Rate of HF hospitalization alone was highest in cluster 1 (36.2%), compared with 23.3% in cluster 2, 17.7% in cluster 3, and 20.9% in cluster 4 (Figure 3). After correction for age, sex, previous HF hospitalization and NYHA class, compared to cluster 1, patients in clusters 2 and 3 had a lower risk of death or HF hospitalization [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.39–0.87; and HR 0.30, 95% CI 0.19–0.48, respectively; online supplementary Table S5].

Discussion

In this study, unsupervised machine learning identified distinct HFpEF clusters based on circulating biomarker profiles. The identified HFpEF clusters were remarkably different in their clinical characteristics and outcomes. Using a novel approach of employing differential expression analysis and pathways analysis on HFpEF clusters, we were able to identify dysregulated biological pathways in each cluster. This is the first study to provide a pathophysiological basis on a proteomic level of clinical phenotypes of HFpEF observed in previous studies (Graphical Abstract).

Previous studies that have identified HFpEF subgroups via cluster analyses have typically done so based on clinical characteristics, echocardiographic and laboratory data (online supplementary Table S6).^{5–9} One such study conducted by Shah et al.⁵ demonstrated that clustering based on clinical data, or 'phenomapping' provided a better discrimination of risk than NT-proBNP and risk scores alone. Nevertheless, studies employing these techniques have not yet assessed the pathophysiology underlying these clinical phenotypes. Our results therefore extend prior studies by providing insights into potential biological mechanisms at a proteomic level, that may underpin the observed clinical phenotypes, thus paving the way to mechanism-based pathophysiologic interventions in specific HFpEF subgroups. The added value of our biomarker-based approach is evident in that patients in different biomarker clusters could have similar echocardiographic and clinical profiles, yet differ drastically in clinical outcome compared to other subgroups. One such example of this is clusters 1 and 2 – both these clusters were elderly patients with multiple age-related comorbidities who had indistinguishable echocardiographic features; yet cluster 2 had a 40% lower adjusted risk of death or HF hospitalization compared to cluster 1.

Clinical correlates of the clusters

The main discriminating clinical parameters identifying each of the biomarker clusters were (i) age; (ii) diabetes and CKD; and (iii) smoking/COPD, and ischaemic aetiology.

Age

Mean age was only 74 years in cluster 3, compared with 79–80 years in the other clusters. This was associated with lower comorbidity burden in cluster 3 patients, except for obesity where there was significantly greater body surface area and a trend towards higher body mass index compared to other clusters. Obokata et al.¹⁵ describe the obese HFpEF phenotype which is characterized by increased concentric left ventricular remodelling, greater left ventricular filling pressures and increased plasma volume despite lower NT-proBNP levels compared to non-obese HFpEF patients. A prospective study from 11 Asian regions sought to identify differences between 'young' (<65 years) and 'elderly' (≥ 75 years) HFpEF patients. This study found that younger age HFpEF was associated with a male majority, higher prevalence of obesity and lower NT-proBNP levels, while left ventricular filling pressures and left ventricular hypertrophy were comparative with elderly HFpEF patients.¹⁰ Similar results were observed in three large HFpEF trials [TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function), I-PRESERVE (Irbesartan in Heart Failure With Preserved Systolic Function), and CHARM-Preserved (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity)], where younger patients with HFpEF were more often obese men, whereas older patients with HFpEF were more often women with a higher prevalence of atrial fibrillation, hypertension, and CKD.¹⁶ Of note, Tromp et al.¹⁷ also found a separate 'elderly/AF HFpEF' cluster, similar to cluster 2 in the present study; while Shah et al.⁵ identified a distinct elderly pheno-group with highest serum creatinine/lowest glomerular filtration rate, and highest natriuretic peptides and MAGGIC risk score values, thus resembling a combination of clusters 1 and 2 in the current study.

Diabetes and chronic kidney disease

Patients in cluster 1 had a substantially higher prevalence of diabetes than cluster 2, 3, and 4. Similarly, Tromp et al.¹⁷ identified a 'lean diabetic HFpEF' cluster with a high prevalence of diabetes and CKD while clustering on comorbidities in a large unselected population of Asian patients with HF. Shah et al.⁵ also identified a diabetes-predominant pheno-group among three HFpEF clusters based on clinical characteristics, although in this US-based cohort the diabetic pheno-group also had the highest prevalence of obesity and obstructive sleep apnoea. High prevalence of CKD, observed in cluster 1 and to a lesser extent in cluster 2, have often been observed in HFpEF populations and represent a high-risk phenotype with a poor prognosis.^{6–9,18} A prospective analysis by Unger et al.¹⁸ in HFpEF patients found that CKD was independently associated with several echocardiographic parameters, including left atrial reservoir strain and left ventricular longitudinal strain, after adjusting for potential cofounders. Development of cardiac




Figure 3 Kaplan–Meier curves for (A) heart failure hospitalization and (B) combined outcome of all-cause mortality and/or heart failure hospitalization at 24 months stratified according to clusters.

abnormalities prior to onset of clinical symptoms in patients with renal dysfunction underpins the hypothesis that the pathogenesis of CKD HFpEF subgroups, such as that identified by cluster 1, may lie with renal dysfunction and its downstream effects.

Smoking/chronic obstructive pulmonary disease and ischaemic aetiology

Cluster 4 was predominantly characterized by a high prevalence of COPD (>40%), double that of the other ‘high-risk’ cluster 1 (<20%), associated with smoking history, ischaemic aetiology in >70% and highest troponin and NT-proBNP levels. Previous studies have not described subgroups of HFpEF patients with pulmonary disease. However, several studies have reported a close association between COPD and HFpEF. The Framingham Heart Study reported that several subclinical non-cardiac organ dysfunctions were associated with increased risk of HF. In particular, ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1:FVC ratio) was associated with incident HFpEF.¹⁹ The importance of the link with smoking history lies in the potential to modify the risk of both COPD and ischaemic heart disease by smoking cessation. Indeed, current or prior smoking was associated with higher prevalence of coronary microvascular dysfunction among patients with HFpEF in PROMIS-HFpEF (Prevalence of Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction).²⁰ Both micro- and macrovascular coronary artery disease may contribute to myocardial ischaemia and worsening HFpEF.²¹ Importantly, revascularization in those with macrovascular coronary artery disease may be associated with preservation of cardiac function and improved outcomes in HFpEF.²¹

Echocardiographic findings

Echocardiography was performed in all patients. We found remarkable similarities in cardiac phenotype between the clusters. Left ventricular size and function and left atrial dimensions were similar

between the clusters. The only discriminating parameter was right ventricular systolic pressure, which was significantly lower in cluster 3, consistent with less severe symptoms and better outcomes in these patients.

Up- and down-regulated biological pathways

Pathways identified by up-regulated biomarkers in cluster 1 were related to cells of both innate and adaptive immunity. Natural killer (NK) cells are important in repairing tissue damage and appear to be preventative against development of fibrosis.²² Chronic decreases in NK cells have been reported to be correlated with low-grade inflammation in the heart.¹⁴ In addition, the T cell-mediated immune response is implicated in cardiac remodelling and the progression of HF.^{23,24} In mice with cardiac hypertrophy, depletion of T cells led to reduced myocardial fibrosis and decreased infiltration of macrophages.²⁴ In a previous cluster analysis, Cohen *et al.*⁹ identified a CKD/DM pheno-group in HFpEF, which also exhibited biomarkers for tumour necrosis factor alpha-mediated inflammation.

Differential expression analysis of cluster 2 did not result in any up- or down-regulated biomarkers relative to the other clusters at a fold-change of 0.8. Considering the overlap in clinical phenotype of clusters 1 and 2, we postulate that this may have overshadowed any differential expression of biomarkers in cluster 2.

Several significant pathways identified in cluster 4 were related to phosphoinositide 3-kinases (PI3K) and their downstream effects. These effects include signalling pathways involved in protein synthesis, cell proliferation, metabolism and cell survival and have been implicated in the pathogenesis of various diseases.^{25,26} Interestingly, increased PI3K/AKT axis activity is postulated to play an important role in cell senescence, which is considered as a key mechanism in COPD pathogenesis.²⁷ A study observed that increased PI3K/AKT axis activity was found in lung tissue and peripheral blood mononuclear cells of COPD patients when compared to controls.²⁸ PI3K

isoforms are found in both cardiomyocytes and leucocytes and have been implemented in pathways influencing hypertrophy, contractility, vascular and myocardial inflammation.²⁹ In addition, AKT effects on monocytes/macrophages are postulated to have an effect on atherosclerosis formation, with increased AKT signalling postulated to accelerate atherosclerosis.²⁶ We postulate that increased PI3K/AKT axis in airway obstruction could have adverse effects on the heart and endothelium, leading to the development of HF.

Strengths and limitations

The strengths of this study are the use of a large panel of biomarkers from several biological domains. This is especially important for HFpEF for which it is postulated to be a disease highly influenced by cardiac and non-cardiac comorbidities. In addition, by clustering on biomarkers rather on clinical variables, this allows for the identification of potential biological phenotypes that may represent underlying biological heterogeneity in HFpEF and in turn different pathophysiological mechanisms. We acknowledge there are several limitations to this study including the small number of patients and the lack of external validation. BIOSTAT-CHF is also primarily a Caucasian cohort and the extent to which the results of this study represent the general HFpEF population is unclear. Despite a lack of external validation, there does appear to be overlap between the results of cluster analyses and subgroups previously identified in other studies, suggesting that there is commonality across different methods and cohorts. We aim to validate our findings in further studies.

Conclusion

Using unsupervised cluster analysis based on a broad range of circulating biomarkers, we identified four distinct clusters of HFpEF with remarkable differences in clinical characteristics and outcomes, potentially reflecting differences in underlying pathophysiology. Cluster 1 patients can be identified as those with diabetic nephropathy, high event rates and a specific activation of inflammatory pathways; cluster 2 are the elderly patients with frequent age-related comorbidities; cluster 3 are young with low burden of comorbidities except obesity, lowest NT-proBNP levels and lowest risk of adverse outcomes; and cluster 4 are those with ischaemic aetiology, smoking and chronic lung disease, most symptoms, as well as highest NT-proBNP and troponin levels, characterized by increased activity of the PI3K/AKT pathway and with the highest risk of death and/or HF hospitalization. Left ventricular and atrial size and function did not differ among groups. These data provide a pathophysiological basis on a proteomic level of clinical phenotypes of HFpEF observed in previous studies, and thus open the door to mechanism-based pathophysiological interventions in specific HFpEF subgroups.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Funding

This work was supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON2014-11 RECONNECT).

Conflict of interest: S.D.A. reports receiving grant support from Abbott and Vifor Pharma, and fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Servier, and Vifor Pharma. G.F. reports being a committee member in trials sponsored by Medtronic, Vifor, Servier, Novartis, and BI, outside the submitted work. M.M. received consulting honoraria from Abbott Vascular, Actelion, Amgen, AstraZeneca, Bayer, Edwards Therapeutics, Servier, Vifor Pharma, WindTree for participation in trials committees or speeches at sponsored meetings. C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Eko.ai Pte Ltd, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC; and serves as co-founder and non-executive director of Eko.ai Pte Ltd. All other authors have nothing to disclose.

References

- Lewis GA, Schelbert EB, Williams SG, Cunnington C, Ahmed F, McDonagh TA, Miller CA. Biological phenotypes of heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2017;**70**:2186–2200.
- Lam CS, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. *Eur Heart J* 2018;**39**:2780–2792.
- Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiadu M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *Eur Heart J* 2014;**35**:2797–2815.
- Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013;**62**:263–271.
- Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiadu M, Bonow RO, Huang CC, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation* 2015;**131**:269–279.
- Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld JA. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. *Eur J Heart Fail* 2015;**17**:925–935.
- Segar MW, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, Berry J, Grodin JL, Pandey A. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. *Eur J Heart Fail* 2020;**22**:148–158.
- Hedman ÅK, Hage C, Sharma A, Brosnan MJ, Buckbinder L, Gan LM, Shah SJ, Linde CM, Donal E, Daubert JC, Målarstig A, Ziemek D, Lund L. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. *Heart* 2020;**106**:342–349.
- Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Perner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA. Clinical phenogroups in heart failure

- with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. *JACC Heart Fail* 2020;**8**:172–184.
10. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwilverman AH, Metra M. A systems BIOlogy study to Tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. *Eur J Heart Fail* 2016;**18**:716–726.
 11. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. *J Stat Softw* 2014;**61**:1–36.
 12. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2021. <https://www.R-project.org> (3 March 2021).
 13. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**:e47.
 14. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 2009;**25**:1091–1093.
 15. Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. *Circulation* 2017;**136**:6–19.
 16. Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CS, McMurray JJ. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2019;**74**:601–612.
 17. Tromp J, Tay WT, Ouwerkerk W, Teng TH, Yap J, MacDonald MR, Leineweber K, McMurray JJ, Zile MR, Anand IS, Richards AM, Lam CS; ASIAN-HF Authors. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. *PLoS Med* 2018;**15**:e1002541.
 18. Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail* 2016;**18**:103–112.
 19. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. *Circulation* 2011;**124**:24–30.
 20. Shah SJ, Lam CS, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Ljung Faxén U, Fermer ML, Broberg MA, Gan LM, Lund LH. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. *Eur Heart J* 2018;**39**:3439–3450.
 21. Hwang S-J, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2014;**63**:2817–2827.
 22. Ong S, Rose NR, Čiháková D. Natural killer cells in inflammatory heart disease. *Clin Immunol* 2017;**175**:26–33.
 23. Strassheim D, Dempsey EC, Gerasimovskaya E, Stenmark K, Karoor V. Role of inflammatory cell subtypes in heart failure. *J Immunol Res* 2019;**2019**:2164017.
 24. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. *Circulation* 2015;**131**:1019–1030.
 25. Sala V, Margaria JP, Murabito A, Morello F, Ghigo A, Hirsch E. Therapeutic targeting of PDEs and PI3K in heart failure with preserved ejection fraction (HFpEF). *Curr Heart Fail Rep* 2017;**14**:187–196.
 26. Linton MF, Moslehi JJ, Babaev VR. Akt signaling in macrophage polarization, survival, and atherosclerosis. *Int J Mol Sci* 2019;**20**:2703.
 27. Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. *Thorax* 2015;**70**:482–489.
 28. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010;**182**:897–904.
 29. Ghigo A, Li M. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. *Front Pharmacol* 2015;**6**:169.